Pancreatic Adenocarcinoma Signature Stratification for Treatment
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized multicentre phase II trial with a large translational component. The
trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and
gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal
adenocarcinoma. Integrated into this phase II trial are a number of laboratory components
including molecular profiling, patient derived organoid establishment, and drug testing
sensitivity and other biomarkers.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Cold Spring Harbor Laboratory Dana-Farber Cancer Institute Johns Hopkins University Memorial Sloan Kettering Cancer Center Ontario Institute for Cancer Research Stand Up To Cancer